创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology ELISA Platform: An Innovative Tool for Bioscience Research

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-10 16:31
  • Views:

(Summary description)In the field of bioscience research, enzyme-linked immunosorbent assay (ELISA) is a powerful tool widely used for antigen and antibody detection and quantitative analysis. In recent years, with the advancement and innovation of technology, InnoModels Biotechnology has successfully launched its unique ELISA platform, which provides researchers with a more efficient, accurate and convenient solution.

InnoModels Biotechnology ELISA Platform: An Innovative Tool for Bioscience Research

(Summary description)In the field of bioscience research, enzyme-linked immunosorbent assay (ELISA) is a powerful tool widely used for antigen and antibody detection and quantitative analysis. In recent years, with the advancement and innovation of technology, InnoModels Biotechnology has successfully launched its unique ELISA platform, which provides researchers with a more efficient, accurate and convenient solution.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-10 16:31
  • Views:
Information

In the field of bioscience research, enzyme-linked immunosorbent assay (ELISA) is a powerful tool widely used for antigen and antibody detection and quantitative analysis. In recent years, with the advancement and innovation of technology, InnoModels Biotechnology has successfully launched its unique ELISA platform, which provides researchers with a more efficient, accurate and convenient solution.
The core advantage of InnoModels Biotechnology ELISA platform is its high sensitivity and specificity. The platform adopts advanced enzyme labeling technology and high-purity antibodies, which makes the test results more accurate and reliable. At the same time, the platform also has a high throughput and is able to process multiple samples at the same time, which greatly improves experimental efficiency.

 


In addition to the basic ELISA functions, InnoModels Biotechnology has also added a variety of customized function modules to the platform according to the needs of scientific research. For example, the platform provides a variety of different antigen-antibody pairing options to meet the needs of different research projects. In addition, the platform also supports automated operation, which reduces the error of human operation and improves the repeatability of experiments.
In practical applications, InnoModels Biotechnology ELISA platform has demonstrated its powerful strength. In the field of medical diagnosis, the platform can rapidly and accurately detect pathogen antigens and antibodies, providing strong support for early detection and diagnosis of diseases. In the field of drug development, the platform can efficiently screen and evaluate the effects of drugs, providing important data support for new drug development.
Looking ahead, InnoModels Biotechnology will continue to devote itself to the optimization and innovation of the ELISA platform. The company will increase its investment in R&D and continue to launch more advanced and intelligent ELISA products to provide more comprehensive and efficient services for researchers.
In conclusion, with its high degree of sensitivity, specificity and customization, InnoModels Biotechnology ELISA platform has become an important tool in the field of bioscience research. In the future, the platform will continue to utilize its advantages in the fields of medical diagnosis and drug discovery to provide more innovative possibilities for researchers.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司